BridgeBio Pharma Income After Taxes 2018-2024 | BBIO
BridgeBio Pharma income after taxes from 2018 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
BridgeBio Pharma Annual Income After Taxes
(Millions of US $) |
| 2023 |
$-653 |
| 2022 |
$-485 |
| 2021 |
$-586 |
| 2020 |
$-505 |
| 2019 |
$-289 |
| 2018 |
$-169 |
| 2017 |
$-44 |
BridgeBio Pharma Quarterly Income After Taxes
(Millions of US $) |
| 2024-09-30 |
$-164 |
| 2024-06-30 |
$-76 |
| 2024-03-31 |
$-36 |
| 2023-12-31 |
$-170 |
| 2023-09-30 |
$-179 |
| 2023-06-30 |
$-161 |
| 2023-03-31 |
$-143 |
| 2022-12-31 |
$-141 |
| 2022-09-30 |
$-140 |
| 2022-06-30 |
$-3 |
| 2022-03-31 |
$-201 |
| 2021-12-31 |
$-152 |
| 2021-09-30 |
$-161 |
| 2021-06-30 |
$-102 |
| 2021-03-31 |
$-171 |
| 2020-12-31 |
$-135 |
| 2020-09-30 |
$-130 |
| 2020-06-30 |
$-136 |
| 2020-03-31 |
$-104 |
| 2019-12-31 |
$-84 |
| 2019-09-30 |
$-61 |
| 2019-06-30 |
$-74 |
| 2019-03-31 |
$-69 |
| 2018-12-31 |
|
| 2018-09-30 |
$-42 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
